Appili Therapeutics Inc T.APLI

Alternate Symbol(s): APLIF

Healthcare

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.

TSX:APLI - Post by User

Appili Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Pickheroon Feb 10, 2021 1:56pm

349 Views

Post# 32527207

CHEAPEST Covid 19 Phase 3 Gem with IMMINENT readout

Company expect to submit 2 NDA´s for US Market approval including the covid 19 treatment during the year . Covid 19 drug is currently under review in Canada and approval could hit the wire anyday now .. This terrible underpriced stock has 10 Bagger Upside Potential and even more . STRONG BUY

Market Cap 85 million
Cash $23 Million or Cash for 1+ Year

Company Presentation
https://7343a5f0-1b48-4477-8577-969ff9b4ed06.filesusr.com/ugd/3d295b_2468d721a70a45c0bfaf03f68b748c4c.pdf

Adding to the COVID-19 treatment toolbox
https://www.thechronicleherald.ca/more/business-voice/adding-to-the-covid-19-treatment-toolbox-540087/

User image